8001 Background: c-Met-amplified NSCLC defines a subset of NSCLC that may be sensitive
to the small-molecule tyrosine kinase inhibitor crizotinib, approved multinationally for the …

EXECUTIVE SUMMARY In 2015, approximately 1.7 million Americans received a cancer
diagnosis. 1 In 2030, this number will rise to nearly 2.3 million. 2 Today, approximately two …

… MA Villalona-Calero reports receiving other commercial research support from Guardant
Health and Merck. D. Dix, VM Raymond, and JI Odegaard hold ownership interest (including …

Purpose Mutations in the RET proto-oncogene and vascular endothelial growth factor
receptor (VEGFR) activity are critical in the pathogenesis of medullary thyroid cancer (MTC). …

Purpose Biliary cancers (BCs) carry a poor prognosis, but targeting the RAS/RAF/mitogen-activated
protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) pathway is of …

DNA methylation in the promoter of certain genes is associated with transcriptional silencing.
Methylation affects gene expression directly by interfering with transcription factor binding …

Purpose Patients with chronic lymphocytic leukemia (CLL) with high-risk genomic features
achieve poor outcomes with traditional therapies. A phase I study of a pharmacokinetically …

Purpose Erlotinib is clinically effective in patients with non–small-cell lung cancer (NSCLC)
who have adenocarcinoma, are never or limited former smokers, or have EGFR mutant …

… Ratain, Onyx Pharmaceuticals Research Funding: Ghassan Abou-Alfa, Bayer
Pharmaceuticals; Miguel A. Villalona-Calero, Bayer Pharmaceuticals; Fred Millard, Bayer …

Purpose Maintaining dose-intensity with chemotherapeutic agents is hindered by a number
of adverse effects including asthenia/fatigue. Tumor necrosis factor (TNF) is one of the …